Cargando…
Use of Eculizumab in Transplant-Associated Thrombotic Microangiopathy in a Patient With Polycystic Kidney Disease Immediately Post–Kidney Transplant: A Case Report
Transplant-associated thrombotic microangiopathy (TMA) in the post–organ transplantation setting occurs from a number of potential inciting factors, such as the use of calcineurin inhibitors, ischemic injury, infections, or antibody-mediated rejection leading to unchecked complement activation and e...
Autores principales: | Godara, Amandeep, Migliozzi, Daniel R., Pilichowska, Monika, Goyal, Nitender, Varga, Cindy, Gordon, Craig E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568057/ https://www.ncbi.nlm.nih.gov/pubmed/33089142 http://dx.doi.org/10.1016/j.xkme.2020.06.007 |
Ejemplares similares
-
Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
por: Lanfranco, Luca, et al.
Publicado: (2017) -
Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy
por: Gomez-Ganda, Laura, et al.
Publicado: (2021) -
Characteristics and management of thrombotic microangiopathy in kidney transplantation
por: Cho, Wonyong, et al.
Publicado: (2023) -
Eculizumab in chemotherapy-induced thrombotic microangiopathy
por: Schulte-Kemna, Lena, et al.
Publicado: (2020) -
Thrombotic Microangiopathy in a Kidney Transplant Patient With COVID-19
por: Bascuñana, Arturo, et al.
Publicado: (2020)